Desmopressin Acetate

V2R

1129.27

DMSO ：100 mg/mL (88.55 mM)
Water ：100 mg/mL (88.55 mM)
Ethanol ：100 mg/mL (88.55 mM)

White powder

Desmopressin (DDAVP) is a selective agonist for the vasopressin V2 receptor (V2R), which is coupled to cAMP-dependent signaling. DDAVP induces cAMP-dependent eNOS activation via Ser1177 phosphorylation[1]. DDAVP (at doses ranging from 100 ng/ml to 1 μg/ml) exerts a modest but significant antiproliferative effect on cultured CT-26 and Colo-205 cells.

In vivo, DDAVP (2 μg/kg) reduces accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibits tumor progression in animals surgically implanted in the spleen with CT-26 cells, and causes some reduction in liver metastasis. DDAVP is able to inhibit lung colonization by blood-borne breast cancer cells in an experimental murine model. It dramatically reduces lymph node and lung metastasis in a model of mammary tumor manipulation and surgical excision in mice when administered perioperatively, and also exerts antitumor effects in combination with chemotherapy. DDAVP increases the plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator, and also enhances platelet adhesion to the vessel wall.

醋酸去氨加压素；Desmopressin acetate；1-Deamino-8-D-arginine-vasopressin diacetate

C₄₆H₆₄N₁₄O₁₂S₂.C₂H₄O₂

16789-98-3